Paper Details

  1. Home
  2. Paper Details

Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.

Author: ArdilaFernando, BernalEnrique, CasadellàMaría, CurranAdrià, EcheverriaPatricia, EstradaVicente, FanciulliChiara, GutierrezAngela, HernándezCristina, Hidalgo-TenorioCarmen, ImazArkaitz, KnobelHernando, LagardeMaría, Lopez-LirolaAna, MaciasJuan, MasiáMar, Montero-AlonsoMarta, MoranoLuis, Navarro-AlcarazAntonio, PareraMariona, PodzamczerDaniel, PortillaJoaquín, PrietoPaula, RigoRaúl, RiveroAntonio, TroyaJesús, ValenciaEulalia, VivancosMaría Jesús

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

BIC/FTC/TAF + darunavir/cobicistat was an effective and well-tolerated regimen for heavily pre-treated people living with HIV, achieving viral suppression in 95% of patients. A modest increase in bictegravir plasma concentration and a decrease in eGFR at Week 4 were observed.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To evaluate the efficacy and safety of the two-pill regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching strategy in heavily treatment-experienced people living with HIV (PLWH). METHODS: Multicentre, prospective, single-arm pilot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkad285

データ提供：米国国立医学図書館（NLM）

Evaluating a Switching Strategy for Heavily Treatment-Experienced HIV Patients

This research delves into the world of [HIV treatment] and [antiretroviral therapy], exploring the efficacy and safety of a new treatment regimen for heavily treatment-experienced individuals living with HIV. The researchers utilized a [prospective, single-arm pilot clinical trial] design to assess the effectiveness of switching from complex multi-drug regimens to a two-pill regimen consisting of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat. The study found that [the two-pill regimen was effective and well-tolerated in heavily treatment-experienced HIV patients], achieving sustained viral suppression in the majority of participants.

Hope for a Simpler HIV Treatment Regimen

The study's results offer hope for [simplifying HIV treatment] for individuals who have been on complex multi-drug regimens for extended periods. The study's findings suggest that [the two-pill regimen may offer a more convenient and tolerable option for heavily treatment-experienced patients].

Navigating the Desert of HIV Treatment

Just as a camel navigates the vast desert, researchers are constantly seeking new routes to combat HIV infection. This study represents an exciting step towards [simplifying and improving treatment options for individuals living with HIV].

Dr.Camel's Conclusion

This study provides valuable insights into a promising new treatment regimen for HIV patients. The findings suggest that [the two-pill regimen may offer a more convenient and effective treatment option for individuals living with HIV], offering hope for improved quality of life and long-term management of the disease.

Date :
  1. Date Completed 2023-11-16
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37725999

DOI: Digital Object Identifier

10.1093/jac/dkad285

Related Literature

Article Analysis
・Effects of cobicistat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.